Recently, phase 3 zolbetuximab trial in patients with CLDN18.2 positive (defined as ≥ 75% of tumor cells showing moderate or strong membranous CLDN18 staining), HER2 negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (ClinicalTrials.gov Identifier: SPOTLIGHT; NCT03504397) resulted in significantly prolonged progression-free survival and overall survival [19]. This evidence concerns the gene CLDN18 and neoplasm.